Analytical Overview: Inozyme Pharma Inc (INZY)’s Ratios Tell a Financial Story

Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.

As of close of business last night, Inozyme Pharma Inc’s stock clocked out at $1.06, down -7.83% from its previous closing price of $1.15. In other words, the price has decreased by -$7.83 from its previous closing price. On the day, 0.54 million shares were traded.

Ratios:

To gain a deeper understanding of INZY’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.68 and its Current Ratio is at 7.68. In the meantime, Its Debt-to-Equity ratio is 0.57 whereas as Long-Term Debt/Eq ratio is at 0.51.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Raymond James on December 12, 2024, initiated with a Outperform rating and assigned the stock a target price of $26.

On September 12, 2024, Stifel started tracking the stock assigning a Buy rating and target price of $16.

Insider Transactions:

Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Apr 02 ’24 when Treco Douglas A sold 7,523 shares for $6.94 per share. The transaction valued at 52,210 led to the insider holds 20,665 shares of the business.

Stock Price History:

Over the past 52 weeks, INZY has reached a high of $7.80, while it has fallen to a 52-week low of $1.04. The 50-Day Moving Average of the stock is -36.01%, while the 200-Day Moving Average is calculated to be -72.43%.

Shares Statistics:

A total of 64.18M shares are outstanding, with a floating share count of 43.56M. Insiders hold about 32.20% of the company’s shares, while institutions hold 59.13% stake in the company.

Most Popular